loading page

Convalescent plasma therapy in immunocompromised patients infected with the BA.1 or BA.2 Omicron SARS-CoV-2
  • +19
  • Quentin Richier,
  • Benjamin De Valence De Minardiere,
  • Dorothée Chopin,
  • Emmanuelle Gras,
  • Laura Levi,
  • Yasmine Abi Aad,
  • Jérôme Pacanowski,
  • Jean-Luc Meynard,
  • Léo Plaçais,
  • Dorothée Fey,
  • Priscille Couture,
  • Guillaume Martin-Blondel,
  • Vincent Pestre,
  • Juliette Woessner,
  • Sophie Ancellin,
  • Pierre Weyrich,
  • Benjamin Carpentier,
  • Salim Idri,
  • Pierre Tiberghien,
  • Laure Surgers,
  • Thomas Hueso,
  • Karine Lacombe
Quentin Richier
Sorbonne Universite

Corresponding Author:[email protected]

Author Profile
Benjamin De Valence De Minardiere
APHP
Author Profile
Dorothée Chopin
APHP
Author Profile
Emmanuelle Gras
Sorbonne Universite
Author Profile
Laura Levi
Sorbonne Universite
Author Profile
Yasmine Abi Aad
APHP
Author Profile
Jérôme Pacanowski
APHP
Author Profile
Jean-Luc Meynard
APHP
Author Profile
Léo Plaçais
Université Paris-Saclay
Author Profile
Dorothée Fey
APHP
Author Profile
Priscille Couture
Hopital Foch
Author Profile
Guillaume Martin-Blondel
Paul Sabatier University
Author Profile
Vincent Pestre
Centre Hospitalier d'Avignon
Author Profile
Juliette Woessner
Centre Hospitalier d'Avignon
Author Profile
Sophie Ancellin
Centre Hospitalier d'Auch
Author Profile
Pierre Weyrich
Groupement des Hopitaux de l'Institut Catholique de Lille
Author Profile
Benjamin Carpentier
Groupement des Hopitaux de l'Institut Catholique de Lille
Author Profile
Salim Idri
Etablissement Francais du Sang
Author Profile
Pierre Tiberghien
Etablissement Francais du Sang
Author Profile
Laure Surgers
Sorbonne Universite
Author Profile
Thomas Hueso
APHP
Author Profile
Karine Lacombe
Sorbonne Universite
Author Profile

Abstract

The emergence of SARS-CoV-2 Omicron variant has led to a complete reconfiguration of the therapeutic landscape, with most monoclonal antibodies having lost any neutralization activity. We report here a case series of 75 immunocompromised patients infected by the Omicron variant who benefited of convalescent plasma. At baseline, 49 (68%) of the participants had a WHO score of 5 and 23 (32%) a WHO score of 6. At day 28 the case fatality was 24%. We observed no significant difference in the clinical outcome between patients with hematological malignancies, solid organ transplantation or auto-immune diseases. These promising results require controlled studies.
03 Mar 2023Submitted to Influenza and other respiratory viruses
06 Mar 2023Submission Checks Completed
06 Mar 2023Assigned to Editor
21 Mar 2023Reviewer(s) Assigned
19 Apr 2023Review(s) Completed, Editorial Evaluation Pending
10 Jun 2023Editorial Decision: Revise Major
30 Aug 20231st Revision Received
05 Sep 2023Submission Checks Completed
05 Sep 2023Assigned to Editor
13 Sep 2023Reviewer(s) Assigned
03 Oct 2023Review(s) Completed, Editorial Evaluation Pending